These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 17471018)

  • 1. Benefits of the combination of thalidomide plus cyclophosphamide in hormone refractory prostate cancer patients.
    Al-Chalabi T; Figg WD
    Cancer Biol Ther; 2007 Mar; 6(3):318-9. PubMed ID: 17471018
    [No Abstract]   [Full Text] [Related]  

  • 2. Thalidomide in combination with oral daily cyclophosphamide in patients with pretreated hormone refractory prostate cancer: a phase I clinical trial.
    Di Lorenzo G; Autorino R; De Laurentiis M; Forestieri V; Romano C; Prudente A; Giugliano F; Imbimbo C; Mirone V; De Placido S
    Cancer Biol Ther; 2007 Mar; 6(3):313-7. PubMed ID: 17327701
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The efficacy and safety of docetaxel plus thalidomide vs. docetaxel alone in patients with androgen-independent prostate cancer: a systematic review.
    Chen L; Qiu X; Wang R; Xie X
    Sci Rep; 2014 Apr; 4():4818. PubMed ID: 24769540
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retrospective analysis of an oral combination of dexamethasone, uracil plus tegafur and cyclophosphamide for hormone-refractory prostate cancer.
    Hatano K; Nonomura N; Nishimura K; Kawashima A; Mukai M; Nagahara A; Nakai Y; Nakayama M; Takayama H; Tsujimura A; Okuyama A
    Jpn J Clin Oncol; 2011 Feb; 41(2):253-9. PubMed ID: 21071389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination therapy for first relapse of multiple myeloma.
    Gourd E
    Lancet Oncol; 2018 Nov; 19(11):e587. PubMed ID: 30318317
    [No Abstract]   [Full Text] [Related]  

  • 6. Pre-clinical and clinical evaluation of estramustine, docetaxel and thalidomide combination in androgen-independent prostate cancer.
    Figg WD; Li H; Sissung T; Retter A; Wu S; Gulley JL; Arlen P; Wright JJ; Parnes H; Fedenko K; Latham L; Steinberg SM; Jones E; Chen C; Dahut W
    BJU Int; 2007 May; 99(5):1047-55. PubMed ID: 17437439
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of bortezomib, cyclophosphamide, and dexamethasone (Vel-CD) chemotherapy without and with thalidomide (Vel-CTD) for the treatment of relapsed or refractory multiple myeloma.
    Ahn JS; Yang DH; Jung SH; Park HC; Moon JH; Sohn SK; Bae SY; Kim YK; Kim HJ; Lee JJ;
    Ann Hematol; 2012 Jul; 91(7):1023-30. PubMed ID: 22314843
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II clinical trial of fludarabine and cyclophosphamide followed by thalidomide for angioimmunoblastic T-cell lymphoma. An NCRI clinical trial. CRUK number C17050/A5320.
    Townsend W; Johnson RJ; Pottinger BT; Counsell N; Smith P; Chadwick H; Evans K; Wickham C; Rudin CE;
    Leuk Lymphoma; 2016 Sep; 57(9):2232-4. PubMed ID: 27001186
    [No Abstract]   [Full Text] [Related]  

  • 9. Oral cyclophosphamide and oral hydroxyurea in the treatment of hormone refractory prostate cancer in rats.
    Naik H; Lehr J; Akhtar A; Pienta K
    Anticancer Res; 1994; 14(6B):2681-4. PubMed ID: 7872701
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Therapy for hormone-refractory prostate cancer].
    Nishimura K; Takahara S; Nonomura N; Okuyama A
    Nihon Rinsho; 2002 Dec; 60 Suppl 11():266-71. PubMed ID: 12599583
    [No Abstract]   [Full Text] [Related]  

  • 11. Low-dose thalidomide in combination with oral fludarabine and cyclophosphamide is ineffective in heavily pre-treated patients with chronic lymphocytic leukemia.
    Laurenti L; Piccioni P; Tarnani M; De Padua L; Garzia M; Efremov DG; Piccirillo N; Chiusolo P; Sica S; Leone G
    Leuk Res; 2007 Feb; 31(2):253-6. PubMed ID: 16815546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thalidomide in relapsed/refractory multiple myeloma: pivotal trials conducted outside the United States.
    Dimopoulos MA; Anagnostopoulos A
    Semin Hematol; 2003 Oct; 40(4 Suppl 4):8-16. PubMed ID: 15015891
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II trial of thalidomide and cyclophosphamide in patients with recurrent or refractory pediatric malignancies.
    Gilheeney SW; Lyden DC; Sgouros S; Antunes N; Gerald W; Kramer K; Lis E; Meyers P; Rosen N; Thaler HT; Trippett T; Wexler L; Dunkel IJ
    Pediatr Blood Cancer; 2007 Sep; 49(3):261-5. PubMed ID: 16972243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of taxotere, thalidomide, and prednisolone in patients with hormone-resistant metastatic prostate cancer.
    Rezvani H; Haghighi S; Ghadyani M; Attarian H
    Urol J; 2012; 9(4):673-7. PubMed ID: 23235972
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lenalidomide (Revlimid) combined with continuous oral cyclophosphamide (endoxan) and prednisone (REP) is effective in lenalidomide/dexamethasone-refractory myeloma.
    van de Donk NW; Wittebol S; Minnema MC; Lokhorst HM
    Br J Haematol; 2010 Jan; 148(2):335-7. PubMed ID: 20085583
    [No Abstract]   [Full Text] [Related]  

  • 16. Hormone-refractory metastatic prostatic cancer treated with methotrexate, cyclophosphamide plus adriamycin, cis-platinum plus 5-fluorouracil plus cyclophosphamide. National Prostatic Cancer Project randomized trial.
    Murphy GP; Priore RL; Scardino PT
    Urology; 1988 Jul; 32(1):33-40. PubMed ID: 3291371
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I study of paclitaxel/doxorubicin/ thalidomide in patients with androgen- independent prostate cancer.
    Amato RJ; Sarao H
    Clin Genitourin Cancer; 2006 Mar; 4(4):281-6. PubMed ID: 16729912
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The effect of cyclophosphamide, thalidomide and dexamethasone combination therapy in relapsed/refractory multiple myeloma].
    Gao W; An N; Chen SL
    Zhonghua Nei Ke Za Zhi; 2006 Mar; 45(3):221-2. PubMed ID: 16624158
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating endothelial cells as a therapeutic marker for thalidomide in combined therapy with chemotherapy drugs in a human prostate cancer model.
    Li H; Raia V; Bertolini F; Price DK; Figg WD
    BJU Int; 2008 Apr; 101(7):884-8. PubMed ID: 18070197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination chemotherapy with cyclophosphamide, thalidomide and dexamethasone for patients with refractory, newly diagnosed or relapsed myeloma.
    Sidra G; Williams CD; Russell NH; Zaman S; Myers B; Byrne JL
    Haematologica; 2006 Jun; 91(6):862-3. PubMed ID: 16769594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.